Interferon beta-1b

NRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical Affairs

Retrieved on: 
Monday, December 5, 2022
Therapy, Post-traumatic stress disorder, Medical Affairs Bureau, Sacubitril/valsartan, Schizophrenia, Medicine, Neurological disorder, PMHNP, Food, Executive director, Novartis, Doctor of Philosophy, Wellness, Patient, State university system, NMDA, Dark Enlightenment, FDA Special Protocol Assessment, Interferon beta-1b, Knowledge, Nursing, Stanford University, Bureau of Oceans and International Environmental and Scientific Affairs, FDA, Vanderbilt University, Loxapine, Breakthrough, Forensic psychiatry, Teva Pharmaceuticals, Food and Drug Administration, Ketamine, Senior, Spectrum, Bayer, Boehringer Ingelheim, Juul, Mental health, Depression, Suicide, CNS, Healthcare, Pharmaceutical industry, Management, Secukinumab, Rutgers University, PTSD

She will lead the Company's clinical development program and provide medical oversight across all indications.

Key Points: 
  • She will lead the Company's clinical development program and provide medical oversight across all indications.
  • NRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical Affairs
    "The NRx team is excited to have attracted a clinician with deep experience as an investigator.
  • Dr. Carretta's wealth of knowledge will help drive our mission to develop a first-in-class lifesaving drug for suicidal depression and PTSD.
  • Prior to this role, Dr. Carretta served as the Vice President, Medical and Scientific Affairs at Pendulum Therapeutics.

New Register-based Data on Use of Interferon Beta, Including Rebif®, in Women with Multiple Sclerosis Show No Effect on Pregnancy Outcomes

Retrieved on: 
Wednesday, September 11, 2019
Women, Consumer, Health, Other Health, Cytokines, Medical specialties, Branches of biology, Medicine, Antivirals, Interferon, Multiple sclerosis, Interferon beta-1b, Multiple sclerosis drug pipeline, Rebif®, Multiple Sclerosis, Merck

Results showed no evidence that IFN -exposure before and during pregnancy in women with multiple sclerosis (MS) affected infant birth weight for gestational age and head circumference.

Key Points: 
  • Results showed no evidence that IFN -exposure before and during pregnancy in women with multiple sclerosis (MS) affected infant birth weight for gestational age and head circumference.
  • These data add to our wealth of knowledge to better understand the safety of interferon beta treatment during pregnancy.
  • Rebif (interferon beta-1a) is a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS) and is similar to the interferon beta protein produced by the human body.
  • Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS).

Betaseron - Drug Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 14, 2019
Health, Pharmaceutical, Cytokines, Business intelligence, Strategic management, Interferon beta-1b, SWOT analysis

The "Betaseron - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Betaseron - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.
  • Betaseron Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location.
  • The report also covers the patents information and market exclusivity data, route of synthesis, market competition, and API manufacturers by country.
  • In addition to this, the report also provides the SWOT analysis for Betaseron and emerging therapies in this space.